Regression to the truth: Replication of association in pharmacogenetic studies

Pharmacogenomics

Volumn 4, Issue 2, 2003, Pages 201-207

  Ryan, Stephen G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Molecular epidemiology; Pharmacogenetics; Polymorphism; Population structure; Study design

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; CLOMIPRAMINE; CLOZAPINE; DOPAMINE 3 RECEPTOR; DRUG METABOLIZING ENZYME; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; DECISION MAKING; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DNA DETERMINATION; DRUG RESPONSE; EXPERIMENTAL DESIGN; EXTRAPYRAMIDAL SYMPTOM; GENE DOSAGE; GENE FREQUENCY; GENE REPLICATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SELECTION; GENETIC SIMILARITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPOTHESIS; OUTCOMES RESEARCH; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETIC STRUCTURE; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PUBLICATION BIAS; REPRODUCIBILITY OF RESULTS; SELECTION BIAS;

EID: 0037340725     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.2.201.22631     Document Type: Article

References (32)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
2. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat. Genet. 29, 306-309 (2001).
3. Poirier J, Delisle MC, Quirion R et al.: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92(26), 12260-12264 (1995).
4. Rigaud AS, Traykov L, Caputo L et al.: The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer's disease. Eur. J. Neurol. 7, 255-258 (2000).
5. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molec. Psychiat. 3(6), 508-511 (1998).
6. Yoshida K, Ito K, Sato K et al.: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharm. Biol. Psychiat. 26(2), 383-386 (2002).
7. Lerer B, Segman RH, Fangerau H et al.: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27(1), 105-119 (2002).
8. Bogardus ST Jr, Concato J, Feinstein AR: Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 281(20), 1919-1926 (1999).
9. Stephens JC, Schneider JA, Tanguay DA et al.: Haplotype variation and linkage disequilibrium in 313 human genes. Science 293, 489-493 (2001).
10. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and Afirican-Americans. J. Biol. Chem. 276 (38), 35669-35675 (2001).
11. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 265, 2037-2048 (1994).
12. Morgenstern H, Glazer WM: Identifying risk factors for tardive dyskinesia among long-term out-patients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiat. 50(9), 723-33 (1993).
13. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65, 220-228 (1999).
14. Wilson JF, Weale ME, Smith AC et al.: Population genetic structure of variable drug response. Nat. Genet. 29(3), 265-269 (2001).
15. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 52, 506-513 (1993).
16. Spielman RS, Ewens WJ: A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am. J. Hum. Genet. 62, 450-458 (1998).
17. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P: Association mapping in structured populations. Am. J. Hum. Genet. 67, 170-181 (2000).
18. 18 Olson CM, Rennie D, Cook D et al.: Publication bias in editorial decision making. JAMA 287(21), 2825-2828 (2002).
19. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 337(8746), 867-72 (1991).
20. Ioannidis JP: Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279(4), 281-283 (1998).
21. Vieland VJ: The replication requirement. Nat. Genet. 29(3), 244-245 (2001).
22. 2c adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
23. Louis EJ, Dempster ER: An exact test for Hardy-Weinberg and multiple alleles. Biometrics 43, 805-811 (1987).
24. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
25. Kurata Y, Ieiri I, Kimura M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharm. Ther. 72(2), 209-219 (2002).
26. Heils A, Teufel A, Petri S et al.: Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66(6), 2621-2624 (1996).
27. Lesch K-P, Bengel D, Heils A et al.: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527-1531 (1996).
28. Collier DA, Stober G, Li T et al.: A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiat. 1(6), 453-460 (1996).
29. Ohara K, Nagai M, Tsukamoto T, Tani K, Suzuki Y, Ohara K: Funtional polymorphism in the serotonin transporter promoter at the SLC6A4 locus and mood disorders. Biol. Psychiat. 44, 550-554 (1998).
30. Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ: Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology 150(1), 120-122 (2000).
31. Hariri AR, Mattay VS, Tessitore A et al.: Serotonin transporter genetic variation and the response of the human amygdala. Science 297(5580), 400-4033 (2002).
32. Neumeister A, Konstantinidis A, Stastny J et al.: Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioural responses to tryptophan depletion in healthy women with and without family history of depression. Arch. Gen. Psychiatry 59(7), 613-620 (2002).